contact[at]op2lysis.com

pilelabs
  • The company
  • The Technology
  • Products
  • Indications
  • News
  • Contact
  • Français

Monthly Archives: January 2022

  1. Home
  2. 2022
  3. January
  • adminop2lysis
  • January 2022
  • Corporate
A large number of successes in 2021!

You will find below a retrospective of 2021.

Read More

Articles récents

  • Op2Lysis is a silver sponsor of the WICH 2023 conference and will have the opportunity to give two oral presentations to an expert audience  in cerebral haemorrhage
  • New support from Bpifrance for €1.5M, covering the GMP production of the Drug Substance OptPA, has been obtained
  • Retrospective – 2022 in a nutshell
  • The EIC Accelerator grant agreement has been signed by the European Innovation Council and provides €2.5M support to the O2L-001 development programme
  • Orphan drug designation granted to OptPA for the treatment of non-traumatic spontaneous intracerebral hemorrhage by the European Commission

Archives

  • September 2023
  • July 2023
  • January 2023
  • December 2022
  • September 2022
  • April 2022
  • January 2022

Catégories

  • Corporate
  • Press Release
gym-footer-logo

Biotechnology company that researches and develops innovative medicines

Supported by
europe
bpi
wallonie

SItemap

  • Contact
  • home
  • Indications
  • Legal Notice
  • News
  • Products
  • The company
  • The Technology

Recent Posts

Op2Lysis is a silver sponsor of the WICH 2023 conference and will have the opportunity to give two oral presentations to an expert audience  in cerebral haemorrhage
September 14, 2023
New support from Bpifrance for €1.5M, covering the GMP production of the Drug Substance OptPA, has been obtained
July 07, 2023

Contact

  • FRANCE: 117 avenue Victor Hugo, 92100 Boulogne-Billancourt, France BELGIUM: Légia Park, Boulevard Patience et Beaujonc, 3, 4000 Liège, Belgium

Op2Lysis © 2022 All Rights Reserved – Legal notice – web agency : Bridge Communication